Revenue Recognition Milestone Method Contingent
AnaptysBio, Inc.·Products & Services·1 segment
Breakdown
Segments
Anaptys Bio Generated Anti PD1Jemperli DostarlimabView metric
| Segment | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q1 '24 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Anaptys Bio Generated Anti PD1Jemperli Dostarlimab | $45M | $45M | $45M | $45M | $180M | $180M | $140M | $15M |
| Total | $45M | $45M | $45M | $45M | $180M | $180M | $140M | $15M |